Piramal Pharma Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹2,617.06 crore and net profit of ₹5.03 crore
- Revenue rose 28.1% year on year and 15.3% sequentially.
- Consolidated net profit compared with losses of ₹69.38 crore in Q1 FY27 and ₹99.22 crore in Q2 FY26.
- No exceptional items; limited-review report was unqualified, with certain subsidiary and associate financial information not auditor-reviewed.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e54447f-87b8-4545-a4bd-29046f07059c.pdf